Five-fold increased risk of relapse following breaks in antipsychotic treatment of first episode psychosis

Schizophrenia Research

Volumn 179, Issue , 2017, Pages 50-56

  Winton Brown, Toby T ^a   Elanjithara, Thomas ^a   Power, Paddy ^a   Coentre, Ricardo ^a   Blanco Polaina, Pablo ^a   McGuire, Philip ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RECURRENCE RISK; RELAPSE; REMISSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SOCIAL STATUS; TREATMENT DURATION; YOUNG ADULT; FOLLOW UP; OUTCOME ASSESSMENT; RECURRENT DISEASE; RISK; TIME FACTOR;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; YOUNG ADULT;

EID: 84994429457     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.09.029     Document Type: Article

References (33)

1. Addington, D., Addington, J., Maticka-Tyndale, E., Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry 22 (1993), 39–44.
2. Barnes, T.R.E., Schizophrenia Consensus Group of British Association for Psychopharmacology, Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. (Oxford), 2011, 10.1177/0269881110391123.
3. Bebbington, P.E., Craig, T., Garety, P., Fowler, D., Dunn, G., Colbert, S., Fornells-Ambrojo, M., Kuipers, E., Remission and relapse in psychosis: operational definitions based on case-note data. Psychol. Med. 36 (2006), 1551–1562, 10.1017/S0033291706008579.
4. Coentre, R., Blanco, P., Fontes, S., Power, P., Initial diagnosis and treatment in first-episode psychosis: can an operationalized diagnostic classification system enhance treating clinicians’ diagnosis and the treatment chosen?. Early Interv. Psychiatry 5 (2011), 132–139, 10.1111/j.1751-7893.2010.00247.x.
5. Craig, T.K.J., Garety, P., Power, P., Rahaman, N., Colbert, S., Fornells-Ambrojo, M., Dunn, G., The Lambeth Early Onset (LEO) team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ, 329, 2004, 1067, 10.1136/bmj.38246.594873.7C.
6. David, A., Buchanan, A., Reed, A., Almeida, O., The assessment of insight in psychosis. Br. J. Psychiatry 161 (1992), 599–602, 10.1192/bjp.161.5.599.
7. Gafoor, R., Landau, S., Craig, T.K.J., Elanjithara, T., Power, P., McGuire, P., Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. J. Clin. Psychopharmacol. 30 (2010), 600–606, 10.1097/JCP.0b013e3181f198da.
8. Jones, S.H., Thornicroft, G., Coffey, M., Dunn, G., A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br. J. Psychiatry 166 (1995), 654–659, 10.1192/bjp.166.5.654.
9. Kahn, R.S., Fleischhacker, W.W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I.P.M., Gheorghe, M.D., Rybakowski, J.K., Galderisi, S., Libiger, J., Hummer, M., Dollfus, S., López-Ibor, J.J., Hranov, L.G., Gaebel, W., Peuskens, J., Lindefors, N., Riecher-Rössler, A., Grobbee, D.E., EUFEST Study Group, Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371 (2008), 1085–1097, 10.1016/S0140-6736(08)60486-9.
10. Kane, J.M., Kishimoto, T., Correll, C.U., Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 12 (2013), 216–226, 10.1002/wps.20060.
11. Kay, S.R., Flszbein, A., Opfer, L.A., The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987), 261–276, 10.1093/schbul/13.2.261.
12. Kirkbride, J.B., Barker, D., Cowden, F., Stamps, R., Yang, M., Jones, P.B., Coid, J.W., Psychoses, ethnicity and socio-economic status. Br. J. Psychiatry 193 (2008), 18–24, 10.1192/bjp.bp.107.041566.
13. Kopala, L.C., Good, K.P., Honer, W.G., Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J. Clin. Psychopharmacol. 17 (1997), 308–313.
14. Lambert, M., Conus, P., Cotton, S., Robinson, J., McGorry, P.D., Schimmelmann, B.G., Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis. J. Clin. Psychopharmacol. 30 (2010), 565–572, 10.1097/JCP.0b013e3181f058a0.
15. Lieberman, J.A., Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch. Gen. Psychiatry, 2006, 10.1001/archpsyc.63.10.1069.
16. Malla, A., Norman, R., Schmitz, N., Manchanda, R., Béchard-Evans, L., Takhar, J., Haricharan, R., Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol. Med. 36 (2006), 649–658, 10.1017/S0033291706007379.
17. McGuffin, P., Farmer, A., Harvey, I., A Polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. Arch. Gen. Psychiatry 48 (1991), 764–770, 10.1001/archpsyc.1991.01810320088015.
18. National Collaborating Centre for Mental Health, Schizophrenia: the NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secundary Care. 2010, 10.1111/j.1440-1819.2011.02280.x/full.
19. Oosthuizen, P., Emsley, R., Jadri Turner, H., Keyter, N., A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int. J. Neuropsychopharmacol. 7 (2004), 125–131, 10.1017/S1461145704004262.
20. Perkins, D.O., Gu, H., Weiden, P.J., McEvoy, J.P., Hamer, R.M., Lieberman, J.A., Comparison of Atypicals in First Episode Study Group, Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry 69 (2008), 106–113.
21. Power, P., Iacoponi, E., Reynolds, N., Fisher, H., Russell, M., Garety, P., McGuire, P.K., Craig, T., The Lambeth early onset crisis assessment team study: general practitioner education and access to an early detection team in first-episode psychosis. Br. J. Psychiatry Suppl. 51 (2007), s133–s139, 10.1192/bjp.191.51.s133.
22. Power, P., McGuire, P., Iacoponi, E., Garety, P., Morris, E., Valmaggia, L., Grafton, D., Craig, T., Lambeth Early Onset (LEO) and Outreach & Support in South London (OASIS) service. Early Interv. Psychiatry 1 (2007), 97–103, 10.1111/j.1751-7893.2007.00010.x.
23. Rabiner, C.J., Wegner, J.T., Kane, J.M., Outcome study of first-episode psychosis. I: relapse rates after 1 year. Am. J. Psychiatr. 143 (1986), 1155–1158, 10.1176/ajp.143.9.1155.
24. Robinson, D., Woerner, M.G., Alvir, J.M., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Lieberman, J.A., Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 56 (1999), 241–247.
25. Robinson, D.G., Woerner, M.G., Alvir, J.M.J., Bilder, R.M., Hinrichsen, G.A., Lieberman, J.A., Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 57 (2002), 209–219.
26. Subotnik, K.L., Nuechterlein, K.H., Ventura, J., Gitlin, M.J., Marder, S., Mintz, J., Hellemann, G.S., Thornton, L.A., Singh, I.R., Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am. J. Psychiatry 168 (2011), 286–292, 10.1176/appi.ajp.2010.09010087.
27. Uçok, A., Polat, A., Cakir, S., Genç, A., One year outcome in first episode schizophrenia. Predictors of relapse. Eur. Arch. Psychiatry Clin. Neurosci. 256 (2006), 37–43, 10.1007/s00406-005-0598-2.
28. Weiden, P.J., Olfson, M., Cost of relapse in schizophrenia. Schizophr. Bull. 21 (1995), 419–429.
29. Woods, S.W., Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry, 1899.
30. World Health Organization, International Statistical Classification of Diseases and Health Related Problems (the) ICD-10. 2004.
31. Wunderink, L., Nieboer, R.M., Wiersma, D., Sytema, S., Nienhuis, F.J., Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70 (2013), 913–920, 10.1001/jamapsychiatry.2013.19.
32. Yung, A.R., Yuen, H.P., McGorry, P.D., Phillips, L.J., Kelly, D., Dell'Olio, M., Francey, S.M., Cosgrave, E.M., Killackey, E., Stanford, C., Godfrey, K., Buckby, J., Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. N. Z. J. Psychiatry 39 (2005), 964–971.
33. Zipursky, R.B., Menezes, N.M., Streiner, D.L., Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr. Res. 152 (2014), 408–414, 10.1016/j.schres.2013.08.001.